NCT04393350 2026-04-20
Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma
Emory University
Phase 2 Active not recruiting
Clinical Trials
15 trialsNCT03091192 2026-04-14
Savolitinib vs. Sunitinib in MET-driven PRCC.
AstraZeneca
Phase 3 Active not recruiting
NCT00579514 2026-04-07
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients
Memorial Sloan Kettering Cancer Center
Phase NA Active not recruiting
NCT03678883 2026-04-03
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
NCT06126159 2026-03-20
MRI Functional Imaging Characteristics and Fat Quantification of CT-fat-free Renal Neoplasms: Relationships With Histological Classifications and Molecular Markers
Chang Gung Memorial Hospital
Phase NA Active not recruiting
NCT03185039 2026-03-19
Predictive Impact of MMP2 and MMP9 Levels for Patients With Metastatic Kidney Cancer Treated With Anti-angiogenic Agents
Institut Paoli-Calmettes
Phase NA Active not recruiting
NCT03996850 2026-03-13
SPECT/CT for the Characterization of Renal Masses
Jonsson Comprehensive Cancer Center
Active not recruiting
NCT07000149 2026-03-10
eVOLVE-RCC02
AstraZeneca
Phase 3 Active not recruiting
NCT05946993 2026-03-04
LIAM Mc
University College Cork
Phase NA Active not recruiting
NCT05672459 2026-02-25
A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT06964958 2026-02-24
LASER
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04258462 2026-02-23
Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors
University of California, San Francisco
Phase 2 Active not recruiting
NCT03203473 2026-02-06
Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT02950766 2026-02-03
NeoVax Plus Ipilimumab in Renal Cell Carcinoma
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT01217931 2026-01-30
Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial
M.D. Anderson Cancer Center
Phase 2 Active not recruiting